Stocktoria
Pulmatrix, Inc. PULM
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-03-21
Pulmatrix, Inc. statistics & valuation
Market cap$6.0M
P / B1.6×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | -125.1% | -202.0% | -312.1% | -390.2% |
| Net margin | — | -122.5% | -193.5% | -310.3% | -390.2% |
| FCF margin | — | -142.4% | -228.3% | -320.2% | -384.4% |
| Return on assets | -124.7% | -96.1% | -41.6% | -46.0% | -34.3% |
| Return on equity | -135.5% | -106.8% | -78.5% | -60.5% | -42.5% |
| Current ratio | 12.55 | 10.68 | 5.33 | 7.60 | 12.33 |
| Revenue growth | — | 7.0% | 20.2% | 17.5% | -59.1% |
Source: SEC EDGAR filings · CIK 0001574235 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.